H.C. Wainwright assumes coverage on Akebia Therapeutics stock with buy rating

Published 04/06/2025, 12:06
H.C. Wainwright assumes coverage on Akebia Therapeutics stock with buy rating

On Wednesday, H.C. Wainwright analysts assumed coverage of Akebia Therapeutics (NASDAQ: NASDAQ:AKBA) stock, assigning it a Buy rating and setting a price target of $8.00. The stock has shown remarkable momentum, delivering a 202% return over the past year. The decision reflects confidence in Akebia’s product Vafseo (vadadustat), which is approved for treating anemia in adults with chronic kidney disease (CKD) who are undergoing dialysis. According to InvestingPro data, analysts maintain a Strong Buy consensus with price targets ranging from $6 to $10.

Vafseo has been gaining traction among dialysis organizations, and its launch is expected to counteract the generic impact on Akebia’s other product, Auryxia (ferric citrate), which targets hyperphosphatemia. The company maintains a healthy financial position with a current ratio of 2.23, indicating strong ability to meet short-term obligations. The ongoing rollout of Vafseo is currently focused on dialysis patients, but there is also potential in the non-dialysis segment, with a Phase 3 trial anticipated in the second half of 2025.

The analysts note that by January 2025, contracts covering nearly all U.S. dialysis patients will be in place, setting the stage for Vafseo’s near-term success. The oral tablet form of Vafseo offers dosing flexibility, ranging from 150mg to 600mg, which could drive increased prescriptions.

The report highlights the potential for Vafseo to benefit patients who rely on erythropoiesis-stimulating agents and iron supplementation therapy. The analysts expect further growth facilitated by uptake among dialysis organizations, particularly large ones.

In other recent news, Akebia Therapeutics reported its Q1 2025 earnings, surpassing expectations with an earnings per share (EPS) of $0.03 compared to the anticipated -$0.05. The company’s revenues reached $57.3 million, exceeding the projected $44.38 million. This performance marks a significant turnaround from a net loss of $18 million to a net income of $6.1 million, attributed to strong sales of its products, particularly Vafcio and Auryxia. Akebia also maintains a positive cash position with $113.4 million in cash and equivalents. The company plans to initiate the Phase III VALOR trial in the second half of 2025, aiming to expand its market reach. Analysts from firms like Leerink Partners and Jefferies expressed interest in the company’s progress and future plans. Akebia continues to focus on advancing its HIF-PH inhibitor pipeline while remaining vigilant about potential generic competition for Auryxia.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.